|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 61.94 CNY | -1.95% |
|
-2.88% | +3.98% |
| Jan. 12 | Hengrui Pharma Unit Secures Approval to Conduct Clinical Trial for Hypertension Drug | MT |
| Jan. 12 | Hengrui Pharma's Cancer Drug Obtains China Breakthrough Therapy Designation | MT |
| Capitalization | 412B 59.15B 50.99B 47.47B 44.19B 82.28B 5,367B 88.53B 546B 215B 2,560B 222B 217B 9,347B | P/E ratio 2025 * |
46.4x | P/E ratio 2026 * | 42.3x |
|---|---|---|---|---|---|
| Enterprise value | 373B 53.58B 46.19B 43B 40.03B 74.53B 4,861B 80.19B 495B 195B 2,319B 201B 197B 8,467B | EV / Sales 2025 * |
11.3x | EV / Sales 2026 * | 9.93x |
| Free-Float |
52.38% | Yield 2025 * |
0.45% | Yield 2026 * | 0.51% |
| 1 day | -1.95% | ||
| 1 week | -2.88% | ||
| Current month | +3.98% | ||
| 1 month | +2.72% | ||
| 3 months | -4.85% | ||
| 6 months | +7.29% | ||
| Current year | +3.98% |
| 1 week | 61.66 |  | 65.83 |
| 1 month | 59.5 | | 65.83 |
| Current year | 59.99 | | 65.83 |
| 1 year | 43.28 | | 74.04 |
| 3 years | 35.51 | | 74.04 |
| 5 years | 27 | | 94.69 |
| 10 years | 12.9 | | 97.39 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jian Jun Liu
DFI | Director of Finance/CFO | 49 | 2021-11-18 |
Ji Feng
PSD | President | - | 2025-04-01 |
Yu Xu
CMP | Compliance Officer | 34 | 2021-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Jie Ping Sun
BRD | Director/Board Member | 56 | 2020-01-15 |
Hong Bin Dai
BRD | Director/Board Member | 50 | 2020-01-15 |
Piao Yang Sun
CHM | Chairman | 67 | 2021-07-07 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -19.71% | 4.18% | 0 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.95% | -2.88% | +44.58% | +46.85% | 59.15B | |
| +0.53% | -2.37% | +43.09% | +190.27% | 930B | |
| -0.41% | +6.98% | +48.72% | +26.86% | 527B | |
| -0.31% | -2.60% | +24.94% | +40.25% | 379B | |
| +0.93% | +2.38% | +31.46% | +18.47% | 371B | |
| +0.19% | -1.15% | +28.47% | +21.14% | 292B | |
| +0.98% | +1.37% | +29.42% | +35.03% | 276B | |
| -1.93% | -1.54% | +11.14% | -1.47% | 270B | |
| +6.49% | +1.95% | -32.44% | -18.44% | 268B | |
| +0.12% | +1.32% | +21.43% | +22.64% | 178B | |
| Average | +0.46% | +0.34% | +25.08% | +38.16% | 355.01B | |
| Weighted average by Cap. | +0.55% | +0.45% | +29.31% | +64.92% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 33.1B 4.75B 4.09B 3.81B 3.55B 6.61B 431B 7.11B 43.85B 17.29B 206B 17.81B 17.45B 751B | 36.92B 5.3B 4.57B 4.25B 3.96B 7.37B 481B 7.93B 48.91B 19.28B 229B 19.87B 19.46B 837B |
| Net income | 8.76B 1.26B 1.08B 1.01B 939M 1.75B 114B 1.88B 11.6B 4.57B 54.39B 4.71B 4.62B 199B | 9.72B 1.39B 1.2B 1.12B 1.04B 1.94B 127B 2.09B 12.88B 5.08B 60.37B 5.23B 5.12B 220B |
| Net Debt | -38.82B -5.57B -4.8B -4.47B -4.16B -7.75B -505B -8.34B -51.42B -20.28B -241B -20.89B -20.46B -880B | -45.64B -6.55B -5.65B -5.26B -4.89B -9.11B -594B -9.8B -60.46B -23.84B -283B -24.56B -24.06B -1,035B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-16 | 61.94 ¥ | -1.95% | 52,378,620 |
| 26-01-15 | 63.17 ¥ | -0.69% | 46,761,230 |
| 26-01-14 | 63.61 ¥ | -1.41% | 62,925,530 |
| 26-01-13 | 64.52 ¥ | +1.05% | 74,034,030 |
| 26-01-12 | 63.85 ¥ | +0.11% | 42,877,010 |
End-of-day quote Shanghai S.E., January 15, 2026
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 600276 Stock
Select your edition
All financial news and data tailored to specific country editions
